Journal of Thrombosis and Thrombolysis

, Volume 3, Issue 2, pp 145–149 | Cite as

New therapeutic opportunities for heparins: What does low molecular weight heparin offer?

  • A. G. G. Turpie
Article

Abstract

New advances in antithrombotic therapy include direct thrombin inhibitors and low molecular weight heparins and heparinoids. Low molecular weight heparins and heparinoids have improved pharmacologic and pharmacokinetic properties when compared with unfractionated heparin. Low-molecular weight heparins are effective in the prevention of venous thromboembolism in general surgical patients, orthopedic patients, spinal cord injury patients, and general medical patients. At equipotent antithrombotic doses, low molecular weight heparins produce less bleeding. Low molecular weight heparins given in fixed doses subcutaneously have been shown to be as effective or more effective and safer than unfractionated heparin given intravenously with regular monitoring in the treatment of venous thromboembolic disease. Recent studies have demonstrated that low molecular weight heparins are effective in reducing the risk of death and myocardial infarction in patients with unstable angina and are as effective as intravenous heparin when given subcutaneously without monitoring. Preliminary data indicate that low molecular weight heparins may be effective in improving outcomes in patients with ischemic stroke.

Key Words

heparin low molecular weight heparin antithrombotic therapy venous thrombosis unstable angina ischemic stroke 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirsh J. Drug therapy. Heparin. N Engl J Med 1991;324:1565–1574.Google Scholar
  2. 2.
    Hirsh J, Levine M. Low molecular weight heparin. Blood 1992;79:1–17.Google Scholar
  3. 3.
    Collins R, Scrimgeous A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery. N Engl J Med 1988;318:1162–1173.Google Scholar
  4. 4.
    Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152–156.Google Scholar
  5. 5.
    Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:335S-315S.Google Scholar
  6. 6.
    Brandjes DPM, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW, Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992;327:1485–1489.Google Scholar
  7. 7.
    Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293–1296.Google Scholar
  8. 8.
    Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260–1264.Google Scholar
  9. 9.
    Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865–1875.Google Scholar
  10. 10.
    Duroux P, Ninet J, Bachet P, et al. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251–256.Google Scholar
  11. 11.
    Bratt G, Tornebohn E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813–817.Google Scholar
  12. 12.
    Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep vein thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:30–37.Google Scholar
  13. 13.
    Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441–445.Google Scholar
  14. 14.
    Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous lowmolecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975–982.Google Scholar
  15. 15.
    Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995;155:601–607.Google Scholar
  16. 16.
    Levine M, Gent M, Hirsh J, et al. A comparison of lowmolecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334(11):677–681.Google Scholar
  17. 17.
    Koopman MMW, Prandoni P, Piovella F, et al. (for the TASMAN Study Group). Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecularweight heparin administered at home. N Engl J Med 1996;334(11):682–687.Google Scholar
  18. 18.
    Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326:310–318.Google Scholar
  19. 19.
    Weitz JI, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993;122:364–373.Google Scholar
  20. 20.
    Bashour TT, Myler RK, Andreae GE, Sterzer SH, Clark DA, Ryan CJM. Current concepts in unstable myocardial ischaemia. Am Heart J 1988;115:850–916.Google Scholar
  21. 21.
    Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225–1230.Google Scholar
  22. 22.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988;319:1105–1111.Google Scholar
  23. 23.
    Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141–145.Google Scholar
  24. 24.
    Theroux P, Waters D, Qiu S, McCans J, et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045–2048.Google Scholar
  25. 25.
    Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994;89:81–88.Google Scholar
  26. 26.
    Gurfinkel EP, Manos EJ, Mejail R, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313–318.Google Scholar
  27. 27.
    Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular weight heparin during instability in coronary artery disease. The Lancet 1996;347:561–568.Google Scholar
  28. 28.
    Turpie AGG, Ruddy T, Sussex BA, et al. Low molecular weight heparin (Dalteparin) in unstable coronary artery disease (FRIC). Can J Cardiol 1995;11Suppl E-:110E.Google Scholar
  29. 29.
    Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin in ischemic stroke. FISS STUDY. N Engl J Med 1995;333(4):1588–1593.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • A. G. G. Turpie
    • 1
  1. 1.Master UniversityHamiltonCanada

Personalised recommendations